Palabras clave
Lupus eritematoso sistémico
Enfermedades Intestinales Crohn disease
Lupus erythematosus
Systemic
Intestinal diseases
Cómo citar
Resumen
La enfermedad inflamatoria intestinal consta de dos patologías base: la enfermedad de Crohn y la colitis ulcerativa idiopática. Como bien se sabe, las enfermedades autoinmunes suelen sobreponerse con otros padecimientos autoinmunitarios. El objetivo de este artículo es revisar la relación entre la enfermedad de Crohn y su coexistencia con otras enfermedades, especialmente con el lupus eritematoso sistémico. Presentamos un caso clínico.
Citas
Cabré E, Domènech E. Manifestaciones y complicaciones extraintestinales de la enfermedad inflamatoria intestinal. En: Montoro Miguel A.; García Pagán Juan Carlos. Problemas Comunes en la Práctica Clínica - Gastroenterología y Hepatología. 2ª edición. España: Jarpyo Editores; 2006. P.483-496
Mateu P, Vilaplana C. Enfermedad de Crohn. En: Julio Ponce García. Tratamiento de las enfermedades gastroenterologicas. 3ª edición. Elsevier; 2011 P. 293-304.
Aguirre D, Archila P, Carrera J, Cataño R. Consenso Colombiano de Enfermedad Inflamatoria Intestinal. Rev Col Gastroenterol vol.27 supl.1 Sept. 2012. P. 1-48.
Juliao F, Ruiz M, Flórez J, Donado H, Marín J, Monsalve C. Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medellín-Colombia. Rev Col Gastroenterol. 2010; 25(3): 240-251.
Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6:1105. https://doi.org/10.1016/j.cgh.2008.04.032
Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730. https://doi.org/10.1111/j.1572-0241.2001.03931.x
Sandborn WJ, Loftus EV, Colombel JF. Utility of perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-saccharomyces cerevesiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (abstract). Gastroenterology 2000; 118:A106. https://doi.org/10.1016/S0016-5085(00)82501-9
Li W, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5.
Sonu I, Blonski W, Lichtenstei G. Papillary thyroid cancer and inflammatory bowel disease: Is there a relationship? WJG 2013; 19(7): 1079-1084. https://doi.org/10.3748/wjg.v19.i7.1079
Zippi M, Pica R, De Nitto D. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol 2014; 20(46): 17463-17467. https://doi.org/10.3748/wjg.v20.i46.17463
Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010; 16:2971. https://doi.org/10.3748/wjg.v16.i24.2971
Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010; 16:2971. https://doi.org/10.3748/wjg.v16.i24.2971
Ceccato F, Salas A, Góngora V, et al. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases. Clin Rheumatol 2008; 27:399. https://doi.org/10.1007/s10067-007-0760-5
Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 2013; 5:210.
https://doi.org/10.1177/1759720X13485503
Mok MY, Wong RW, Lau CS. Intestinal pseudo-obstruction in systemic lupus erythematosus: an uncommon but important clinical manifestation. Lupus 2000; 9:11. https://doi.org/10.1177/096120330000900104
Katsanos K, Voulgari P, Goussia A,Oikonomou P, Christodoulou D, Drosos A, Tsianos E. Coexistence of Crohn's disease in a patient with systemic lupus erythematosus. Rheumatol Int (2013) 33:2145-2148 https://doi.org/10.1007/s00296-011-2357-1
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. ACR. Marzo/22/16 ; 25:1271-7. Disponible en: http://www.rheumatology.org/Portals/0/Files/1982%20SLE%20Classification_Excerpt.pdf https://doi.org/10.1002/art.1780251101
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721. https://doi.org/10.1016/S0140-6736(10)61354-2